Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis

Journal of Drugs in Dermatology

Volumn 8, Issue 1, 2009, Pages 52-57

  Menter, Alan ^a   Abramovits, William ^b   Colón, Luz E ^c   Johnson, Lori A ^c   Gottschalk, Ronald W ^c  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b Dermatology Treatment and Research Center   (United States)

^c Galderma Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CLOBETASOL PROPIONATE; ANTIINFLAMMATORY AGENT; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE-17,21-DIPROPIONATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; DERMATOLOGICAL AGENT; DRUG DERIVATIVE; GLUCOCORTICOID;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN ABRASION; SKIN BURNING SENSATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; OINTMENT; PATHOLOGY; PSORIASIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; CLOBETASOL; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE;

EID: 60849103772     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Beutner K, Chakrabarty A, Lemke S, et al. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol. 2006;5:357-360.
2. Kiec-Swierczynska M, Dudek B, Krecisz B, et al. [The role of psychological factors and psychiatric disorders in skin diseases]. Med Pr. 2006;57:551-555.
3. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272-284. (Pubitemid 47071926)
4. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-407. (Pubitemid 29418506)
5. Bohjanen KA, Prawer SE. New biologic therapies for psoriatic disease. Minn Med. 2004;87:34-36.
6. Thappa DM, Laxmisha C. Immunomodulators in the treatment of psoriasis. Indian J Dermatol Venereol Leprol. 2004;70:1-9. (Pubitemid 39217016)
7. Stein Gold L, Corvari L. The roles of safety and compliance in determining effectiveness of topical therapy for psoriasis. Cutis. 2007;79(Suppl 2):32-38.
8. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? J Drugs Dermatol. 2006;5:527-532.
9. Center for drug evaluation and reseach, drugs @ fda. http://www. accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Overview&DrugName=CLOBETASOL%20PROPIONATE. Last accessed: May 29, 2008.
10. Jarratt MT, Clark SD, Savin RC, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis. 2006;78(5):348-354. (Pubitemid 44952097)
11. Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147(2):316-323.
12. Kragballe K, van de Kerkhof PC. Consistency of data in six phase iii clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2006;20(1):39-44.
13. Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (daivobet/dovobet/taclonex) in the treatment of psoriasis vulgaris. Dermatology. 2006;213(4):319-326. (Pubitemid 44837020)
14. Feldman SR, Koo JY, Menter A, et al. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol. 2005;53(1):101-107. (Pubitemid 40826702)
15. Ockenfels HM. [trigger factors for psoriasis]. Hautarzt. 2003;54(3):215-223.
16. Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50(3):416-430. (Pubitemid 38316135)
17. van de Kerkhof PC. Psoriasis. ed. St. Louis, MO: Mosby; 2003.
18. Hradil E, Lindstrom C, Moller H. Intermittent treatment of psoriasis with clobetasol propionate. Acta Derm Venereol. 1978;58(4):375-377. (Pubitemid 9008714)
19. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med. Surg 2003;7(3):185-192. (Pubitemid 36859094)
20. Feldman SR. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: Add-on therapy in the cobra trial. Cutis. 2007;80(5 Suppl):20-28.
21. Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (mc 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol. 1992;26(5 Pt 1):736-743.
22. Shupack JL, Jondreau L, Kenny C, et al. Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology. 1993;186(2):129-132. (Pubitemid 23070156)
23. Feldman SR, Gelfand JM, Stein Gold L, Jones SD. The role of topical therapy for patients with extensive psoriasis. Cutis. 2007;79(1 Suppl 2):18-31.
24. Feldman SR and Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol .2003;4(4):221-224. (Pubitemid 36506427)
25. Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: A quantitative assessment of vehicle preference. Cutis. 2002;70(6):327-332. (Pubitemid 41757440)